First published · Last updated
Neoadjuvant Advantage, Adjuvant Challenge: Clinical Evidence and Hypothetical Biological Mechanisms Behind Divergent Tolerability
A journal article published by MDPI examines clinical evidence and proposes hypothetical biological mechanisms to explain differing tolerability between neoadjuvant (preoperative) and adjuvant (postoperative) therapies.
Categories: science-and-space, public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 2/10
- Geographic reach
- 1/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 5/10
- Urgency
- 2/10
Why it matters
The article addresses differences in therapy tolerability that are relevant to clinical decision-making.

